alexa An Old Drug for the Modern Treatment of Leishmaniasis | Open Access Journals
ISSN: 2329-9053
Journal of Molecular Pharmaceutics & Organic Process Research
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

An Old Drug for the Modern Treatment of Leishmaniasis

Claudia Salerno and Carlos Bregni*
Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
Corresponding Author : Carlos Bregni
Department of Pharmaceutical Technology
Faculty of Pharmacy and Biochemistry
University of Buenos Aires, Buenos Aires, Argentina
Tel: +541149648271
Fax: +541149648271
E-mail: [email protected]
Received May 26, 2014; Accepted May 28, 2014; Published May 30, 2014
Citation: Salerno C, Bregni C (2014) An Old Drug for the Modern Treatment of Leishmaniasis. J Mol Pharm Org Process Res 2:e114. doi: 10.4172/2329-9053.1000e114
Copyright: ©2014 Salerno C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Molecular Pharmaceutics & Organic Process Research

Leishmaniasis is a worldwide spread neglected disease caused by Leishmania parasites. Although it is an ancient disease, it has been recently classified as an emerging pathology with 2 million cases annually. It has become a public health problem since several factors favor its expansion such as migration, urbanization and deforestation, co-infection with human immunodeficiency virus and malnutrition, and inadequate vector o reservoir control, treatment failure and emerging drug resistance due to incomplete treatment. Moreover, diagnosis and treatment is not often possible in rural areas where the disease is more frequent. Leishmania parasites can cause four clinical forms: cutaneous (CL), diffuse cutaneous, mucocutaneous, and visceral pathology. Visceral leishmaniasis is the most severe form of the disease; however CL is the most prevalent. CL is caused mostly by L. major in the Old World and by L. Mexicana, L. peruviana, and L. braziliensis in the New World. The prognosis of the disease depends on the Leishmania specie and immunological condition of the patient. Although CL lesions may be self-limited, treatment helps to reduce scars and prevent disease dissemination. Main treatment with parenteral pentavalent antimonials produce serious side effects and patient compliance is difficult. The World Health Organization (WHO) also recommends intralesional treatment with antimonial drugs depending on clinical features. Oral alternatives such as miltefosine, allopurinol and azoles have been used. But, there is still lack of effective topical treatments for CL.
Azole antifungals inhibit a key enzyme for the production of ergosterol, the main sterol in membranes of fungi and parasites. Fluconazole (FLZ) is a bis-triazole antifungal with activity against Candida spp., Blastomyces dermatitidis, Cryptococcus neoformans, Epidermophytom spp., Histoplasma, Microsporum spp. and Trichophyton spp. It has been extensively used in the treatment of dermatophytoses; after oral administration FLZ concentration in the skin is high due to great affinity to the stratum corneum. However, the use of FLZ as topical treatment is not a general practice. Oral FLZ has been reported for the treatment of CL and has shown activity against Leishmania spp.; a six-week course of oral FLZ shortened healing time of L. major cutaneous lesions, but high doses (200 mg/day for 6 weeks) were needed and side effects are of concern. Nevertheless, results are controversial; a study reported that in vitro anti-leishmanial activity of FLZ was poor and a group of researchers compared FLZ topical cream (1, 2, or 10% w/w) and topical paromomycin gel, in BALB/c mice infected with L. amazonensis or L. major, and they concluded that FLZ was ineffective. In the latter case those formulations had propylene glycol and we found in previous works that the presence of this excipient may affect FLZ activity. Moreover, we reported that FLZ penetration and retention within the skin was greater when formulated in a microemulsion (ME) compared with other conventional topical dosage forms such as emulsion or emulgel.
In a preliminary assess of the in vitro activity of a FLZ-ME against Leishmania we found that a FLZ-ME showed similar activity against L. Braziliensis promastigotes than AmB Deoxycholate, a second line drug used for the treatment of CL. It is also important to mention that blank formulation inhibited the parasite growth, but FLZ-ME showed higher inhibition. The synergistic activity may be due to the high content of surfactants which alter membrane fluidity causing electrolyte or other vital substances depletion. This observation was also reported for a micellar formulation with Poloxamer 188. Furthermore, it was published that surfactants had strong lytic effect against Trypanosoma cruzi, a parasite of the same family as Leishmania, and enhanced antiparasitic drugs activity.
Considering these outcomes, we remark the importance of the vehicle on drug activity and also highlight the different drug susceptibility of Leishmania species. Further work is needed, but FLZ could be useful for the local treatment of CL in the New World. This fact is very important as topical alternatives are required to reduce oral and parenteral courses to help patient compliance. Topical treatment would be less expensive, with fewer adverse effects. Modern therapy challenge is to make drugs reach target sites with the minimal adverse effects, consequently treatment of CL needs rational selection of drugs and also an appropriate vehicle.

 

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11738
  • [From(publication date):
    August-2014 - Oct 22, 2017]
  • Breakdown by view type
  • HTML page views : 7914
  • PDF downloads :3824

Review summary

  1. june
    Posted on Jan 13 2017 at 7:12 pm
    Join me celebrate for these great and perfect day which my lord god has done for using these great and powerful healing doctor called doctor Alika to heal my sickness (Leishmaniasis) which has been chocking me up for over 1year now without solutions, i have seek for solutions online, and through hospital, they keep on giving me orientations about drugs that can extand my years.now since doctor alika has helped me to erased my disease out of my life, i we owe you greatly for healing me truly and to again, contact doctor ALIKA for your cure today at: [email protected] EMAIL.. [email protected] Doctor Alika can as well cure the following disease; Genital warts Herpes, Asthma, Cancer, HSV1, & HSV2, Hepatitis B, HIV/AID ETC. You can also Email me @ [email protected]
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords